Navigation Links
BioHorizons Announces Its 2009 Global Symposium: Bringing Together Top Thought Leaders in the Dental Implant Industry to Provide Insight on Integrating Technology into the Continuum of Care
Date:3/24/2009

BIRMINGHAM, Ala., March 24 /PRNewswire/ -- BioHorizons announces today that its 2009 Global Symposium will take place Thursday, April 30, to Saturday, May 2, at the Hilton Chicago. This educational event will focus on recent advances in digital dentistry, treatment planning, implant surface treatments, tissue regeneration and implant specific restorations.

Scientific sessions will bring together the outstanding and diverse expertise of top dental clinicians such as Drs. Carl E. Misch, Michael A. Pikos, Maurice Salama, Edward P. Allen, and Scott Ganz to provide insight into today's most challenging implant and regeneration topics, including technical advances in diagnostic three-dimensional imaging and treatment planning software. Each clinician-moderated session will feature a panel discussion of audience-submitted questions that fosters a highly interactive learning environment. The three days of continuing education will include hands-on training sessions and dedicated educational tracks for auxiliary and office staff.

Presenters and moderators include Drs. Carl E. Misch, Maurice Salama, Michael A. Pikos, Scott Ganz, Edward P. Allen, David Garber, Jack Ricci, Natalie Wong, Ray Yukna, Michael Reddy, Hamid Shafie, Jay Malmquist, Michael Klein, and Murray Arlin.

BioHorizons continues to be one of the fastest growing dental implant companies in the industry because of unique offerings like Laser-Lok(R) microchannels, VIP 2.1 treatment planning software and gold-hued esthetic abutments provided with every bone level implant system. Symposium presentations will illustrate the unique position of BioHorizons to assist dental clinicians throughout the continuum of care.

"Each year, the BioHorizons Global Symposium stimulates invaluable interaction within the dental implant community," said Steve Boggan, BioHorizons President & CEO. "In the current global economic climate, it is important to develop advanced knowledge and strong relationships to achieve superior esthetic results for patients and generate new opportunities for dental practices."

To register and view schedules, detailed session topics and hotel information, go to www.biohorizons.com, or call (866) 872-9785. Register early, attendance will be limited to maintain an environment conducive to learning. This event will offer up to 20 CE credit hours.

About BioHorizons, Inc.

BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including dental implants, surgical planning software, regenerative products, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.


'/>"/>
SOURCE BioHorizons
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
2. BioHorizons Expands to New 44,000 Square Foot Facility
3. BioHorizons Introduces Its New Tapered Internal Implants Featuring Laser-Lok(R) Microgrooves
4. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
5. Maryland Performance Excellence Awards Program Announces Winners of Maryland Quality Awards
6. Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care
7. The 50 Million Pound Challenge Announces One-Millionth Member
8. Robbins & Myers Announces Regular Quarterly Cash Dividend
9. Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2008
10. Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital
11. WorkCompEDI Announces Agreement with Aon eSolutions for Electronic Billing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a tool ... effect without heavy rendering or complicated compositing," said Christina Austin - CEO of Pixel ... an organic spectrum of lights that simulates the look of a glare. Just ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. ... thick and thin. The beauty of the Lithuanian language and its poetry ... this poetry book, Zubinas lyrically explores all aspects of a living, breathing forest where ...
(Date:12/5/2016)... ... 2016 , ... Researchers at Johns Hopkins All Children’s Hospital want to learn ... the course of three years, researchers will study concussions and changes in brain function ... with special sensors, will track the location and force of the hit. The sensors ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... a patent-pending blend of L-Citrulline and glutathione to enhance production of nitric oxide ... that studies have shown to produce NO twice as effectively and sustains NO ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... and geographic lines. The goal of Castlewood Treatment Centers has always been to ... accessible to as many people as possible. In that spirit, Castlewood has announced ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016   BIOTRONIK today announced ... The study evaluates the safety and feasibility of performing ... office setting. BioMonitor 2 is an insertable ... is placed underneath a patient,s skin to help physicians ... Atrial fibrillation is a leading cause of stroke and ...
(Date:12/5/2016)... , Dec. 5, 2016  Wellbridge Health and Gateway Health ... health solutions to Medicare and Medicaid plan members with specific ... at the unique needs of this group of consumers, Wellbridge ... work philosophies to provide insight into members, daily behaviors and ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: